MDT

Based on Medtronic plc's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does Medtronic do?

Medtronic develops and sells device-based medical therapies across three segments: Cardiovascular, Medical Surgical, and Neuroscience. Its products include pacemakers, heart valves, surgical staplers, spinal implants, and robotic surgery platforms. The company sells to hospitals, health systems, and specialist physicians in markets around the world.

Does MDT pay dividends?

Yes, Medtronic pays a regular dividend. It has a long track record of returning capital to shareholders, which is consistent with its profile as a large-cap, mature medical device company. Income-focused investors often consider MDT for this reason. Check Medtronic's investor relations page for the current dividend rate and payment schedule.

When does MDT report earnings?

Medtronic reports earnings on a quarterly cadence, as is standard for large-cap US-listed companies. For the exact date of the next earnings release, refer to Medtronic's investor relations page, which publishes the financial calendar in advance.

Is MDT a good stock to buy?

UQS Score rates MDT as Good overall. The Valuation pillar is a relative strength, while Quality, Moat, Growth, and Risk are all Neutral — suggesting a stable but not standout profile. Whether MDT fits your portfolio depends on your goals. The full pillar breakdown is available to UQS Pro members.

Is MDT overvalued?

Based on the UQS Valuation pillar, MDT is rated Good, indicating the stock does not appear to be trading at a significant premium relative to its fundamentals. This places it in a more favorable valuation position compared to some peers in the medical device sector. Full valuation metrics are available in the Pro analysis.

How does MDT compare to its competitors?

Medtronic is one of the broadest medical device companies by product scope, competing with Boston Scientific in cardiac and endoscopy, Stryker in surgical robotics and orthopedics, and Abbott in cardiac rhythm management. Its diversification is a differentiator, though it also means competing across more categories simultaneously. The UQS competitor comparison module shows relative scoring.

What is MDT's market cap bracket?

Medtronic is classified as a large-cap company. This places it among the larger publicly traded medical device companies globally, with the scale, institutional coverage, and balance sheet size typically associated with that bracket.

Who founded Medtronic?

Medtronic was founded by Earl Bakken and Palmer Hermundslie. The company has grown from a small medical equipment repair shop into one of the world's largest medical device manufacturers. Its founding history is widely documented and available through Medtronic's own corporate history resources.

Is MDT a long-term quality holding?

As a long-term quality indicator, MDT's UQS profile shows a balanced but Neutral reading across most pillars, with Valuation rated Good. Long-term investors focused on quality metrics will want to monitor whether the Growth and Moat pillars strengthen over time, particularly as the company advances its robotic and AI-enabled platforms.

What is the main competitive advantage of Medtronic?

Medtronic's primary competitive advantages include its global commercial scale, deep relationships with hospital systems and specialist physicians, and a broad intellectual property portfolio built over decades. However, its Moat pillar is currently rated Neutral, suggesting these advantages face real competitive pressure from focused rivals in each of its major segments.

What sector does MDT belong to?

Medtronic operates in the Healthcare sector, specifically within the medical devices and equipment industry. It is one of the largest companies in that industry globally, with exposure to cardiovascular, surgical, and neuroscience device markets across both developed and emerging economies.

Medtronic plc has average quality metrics, with room for improvement in margins or capital efficiency.

Medtronic plc faces growth headwinds with declining or stagnant revenue trends.

Medtronic plc maintains a reasonable risk profile with manageable debt levels.

Medtronic plc has a mixed valuation — some metrics suggest fair value while others appear stretched.

Medtronic plc possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for MDT.

The UQS (Unified Quality Score) for Medtronic plc is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Medtronic plc's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Medtronic plc is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.